Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials

Current Medical Research and Opinion

Volumn 25, Issue 12, 2009, Pages 3029-3036

  Jenkins, Stephen G ^a   Fisher, Alan C ^b   Peterson, Janet A ^b   Nicholson, Susan C ^b   Kaniga, Koné ^c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Carbapenem; Doripenem; Infection; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; CIPROFLOXACIN; DORIPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ACUTE RESPIRATORY TRACT DISEASE; ADD ON THERAPY; ANTIBIOTIC SENSITIVITY; ARTICLE; CARDIOPULMONARY ARREST; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HOSPITAL INFECTION; HUMAN; LUNG EMBOLISM; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE ORGAN FAILURE; PNEUMONIA; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SEPSIS; SEPTIC SHOCK; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CLINICAL TRIALS, PHASE III AS TOPIC; CROSS INFECTION; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72549093543     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903396790     Document Type: Article

References (30)

1. Carmeli Y. Strategies for managing today's infections. Clin Microbiol Infect 2008;14(Suppl. 3):22-31
2. Rossolini GM, Mantengoli E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 2005;11(Suppl. 4):17-32 (Pubitemid 40946169)
3. Garau J, Gomez L. Pseudomonas aeruginosa pneumonia. Curr Opin Infect Dis 2003;16:135-143
4. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12
5. Infectious Diseases Society of America. Bad Bugs, No Drugs As Antibiotic Discovery Stagnates . . . A Public Health Crisis Brews. Alexandria, VA: Infectious Diseases Society of America, 2004
6. Zhanel GG, DeCorby M, Laing N, et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006. Antimicrob Agents Chemother 2008;52:1430-1437
7. Lockhart SR, Abramson MA, Beekmann SE, et al. Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J Clin Microbiol 2007;45:3352-3359
8. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(Suppl. 4):S131-S138
9. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-474 (Pubitemid 29083057)
10. Ibrahim EH, Sherman G, Ward S, et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-155 (Pubitemid 30485502)
11. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin Microbiol Infect 2005;11:974-984
12. Ge Y, Wikler MA, Sahm DF, et al. In vitro antimicrobial activity of doripenem, a new carbapenem. Antimicrob Agents Chemother 2004;48:1384-1396
13. Jones RN, Huynh HK, Biedenbach DJ. Activities of doripenem (S-4661) against drug-resistant clinical pathogens. Antimicrob Agents Chemother 2004;48:3136-3140
14. Wexler HM, Engel AE, Glass D, et al. In vitro activities of doripenem and comparator agents against 364 anaerobic clinical isolates. Antimicrob Agents Chemother 2005;49:4413-4417
15. Lister PD. Carbapenems in the USA: focus on doripenem. Expert Rev Anti Infect Ther 2007;5:793-809
16. Nicolau DP. Carbapenems: a potent class of antibiotics. Expert Opin Pharmacother 2008;9:23-37
17. Pillar CM, Torres MK, Brown NP, et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008;52:4388-4399
18. Lucasti C, Jasovich A, Umeh O, et al. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008;30:868-883 (Pubitemid 351799866)
19. Malafaia O, Umeh O, Jiang J, et al. Doripenem versus meropenem for the treatment of complicated intra-abdominal infections. Presented at: 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Sept. 27-30, 2006, San Francisco, CA
20. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study. Curr Med Res Opin 2008;24:2113-2126
21. Chastre J, Wunderink R, Prokocimer P, et al. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008;36:1089-1096
22. Doribax® (doripenem for injection) package insert. Ortho-McNeil Pharmaceuticals, Inc., Raritan, NJ, 2009
23. Primaxin® IV (imipenem and cilastatin for injection) package insert. Merck & Co., Inc., Whitehouse Station, NJ, 2009
24. Levaquin® (levofloxacin) package insert. Ortho-McNeil Pharmaceuticals, Inc., Raritan, NJ, 2008
25. Merrem® (meropenem for injection) package insert. AstraZeneca Pharmaceuticals, Inc., Wilmington, DE, 2007
26. Zosyn® (piperacillin/tazobactam for injection) package insert. Wyeth Pharmaceuticals Inc., Philadelphia, PA, 2007
27. SAS Institute Inc. SAS/STAT User's Guide. SAS Institute Inc., Cary, NC, 1999
28. Fleiss JL, Levin B, Paik MC. Combining evidence from fourfold tables. In: Fleiss JL, Levin B, Paik MC (eds). Statistical Methods for Rates and Proportions. New York, NY: John Wiley & Sons, Inc., 2003:234-283
29. Merchant S, Gast C, Nathwani D, et al. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin Ther 2008;30:717-733 (Pubitemid 351680488)
30. Kollef KE, Schramm GE, Wills AR, et al. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008;134:281-287